Vas Narasimhan
All peopleVas Narasimhan, full AI read
Vas Narasimhan, CEO, Novartis (Switzerland), ranks #447/500 on the Power & Influence Index (43.0). Entrenchment 64/100.
Dimension read
| Dimension | Value | Standing | What a high vs low value means, and where Vas Narasimhan sits |
|---|---|---|---|
| PII Power & Influence (PII) | 43.0 | Developing · #443/635 | Low here, lower relative influence within this elite set. ▲ high: near the apex of civilizational influence · ▼ low: lower relative influence within this elite set |
| Economic power Economic power | 54.0 | Moderate · #398/635 | Mid-pack. High would mean controls vast wealth and companies; low would mean limited economic control. ▲ high: controls vast wealth and companies · ▼ low: limited economic control |
| Political power Political power | 44.0 | Moderate · #403/635 | Mid-pack. High would mean commands states, law or policy; low would mean little formal political power. ▲ high: commands states, law or policy · ▼ low: little formal political power |
| AI power AI power | 42.0 | Moderate · #323/635 | Mid-pack. High would mean shapes or controls the trajectory of AI; low would mean limited sway over AI's direction. ▲ high: shapes or controls the trajectory of AI · ▼ low: limited sway over AI's direction |
| Platform reach Platform reach | 40.0 | Developing · #453/635 | Low here, limited direct reach. ▲ high: commands a vast audience or network · ▼ low: limited direct reach |
| Institutional control Institutional control | 56.0 | Developing · #499/635 | Low here, limited institutional control. ▲ high: controls pivotal institutions and capital · ▼ low: limited institutional control |
| Entrenchment / tenure Entrenchment / tenure | 64.0 | Moderate · #296/635 | Mid-pack. High would mean power is locked in (indefinite or controlling stake); low would mean power is contingent, term-limited or contestable. ▲ high: power is locked in (indefinite or controlling stake) · ▼ low: power is contingent, term-limited or contestable |
Strengths
- No standout dimension.
Risk factors
- Significant but balanced influence with no single dominant lever.
AI worldview
Ideas & positions
Vas Narasimhan, CEO of Novartis, emphasizes the transformative potential of AI in pharmaceuticals, particularly in drug discovery and personalized medicine. He has publicly supported the integration of AI to accelerate research and development processes, improve patient outcomes, and enhance operational efficiency. Narasimhan has not taken a strong stance on existential risk, open vs closed models, or specific regulatory frameworks for AI, but he has highlighted the importance of ethical considerations and collaboration between industry, academia, and government. In 2019, Novartis partnered with Microsoft to advance AI in drug discovery and development.
What shapes the view
Narasimhan's views are shaped by his background in medicine and his experience leading a global pharmaceutical company. His focus on innovation and technology is driven by the need to address complex health challenges and improve patient care. He advocates for a balanced approach to AI, emphasizing the need for responsible development and deployment while recognizing the significant benefits AI can bring to healthcare.
The AI-powered future they see
Narasimhan envisions a future where AI plays a central role in the discovery and development of new treatments, enabling more precise and effective therapies. He predicts that AI will revolutionize clinical trials, making them faster and more efficient, and will help in identifying new targets for drug development. He also sees AI as a tool to personalize medicine, tailoring treatments to individual patients based on their genetic and molecular profiles.